These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1202 related items for PubMed ID: 34661758

  • 1. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
    Zhao Y, Wang H, He C.
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
    [Abstract] [Full Text] [Related]

  • 2. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
    Kim WY, Prudkin L, Feng L, Kim ES, Hennessy B, Lee JS, Lee JJ, Glisson B, Lippman SM, Wistuba II, Hong WK, Lee HY.
    Cancer; 2012 Aug 15; 118(16):3993-4003. PubMed ID: 22359227
    [Abstract] [Full Text] [Related]

  • 3. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F, Diao XY, Zhang X, Shao Q, Feng YF, An X, Wang HY.
    Cancer Commun (Lond); 2019 Mar 02; 39(1):7. PubMed ID: 30823937
    [Abstract] [Full Text] [Related]

  • 4. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
    Jotte RM, Spigel DR.
    Cancer Med; 2015 Nov 02; 4(11):1621-32. PubMed ID: 26310719
    [Abstract] [Full Text] [Related]

  • 5. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K, Yuan Q.
    J Cancer Res Ther; 2016 Dec 02; 12(Supplement):C131-C137. PubMed ID: 28230005
    [Abstract] [Full Text] [Related]

  • 6. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J, Wang J, Zeng Y, Zhang X, Hu Q, Zheng J, Chen B, Xie B, Zhang WM.
    Oncotarget; 2015 Dec 29; 6(42):44332-45. PubMed ID: 26554308
    [Abstract] [Full Text] [Related]

  • 7. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ, Drilon A, Santini FC.
    Lung Cancer; 2019 Nov 29; 137():113-122. PubMed ID: 31568888
    [Abstract] [Full Text] [Related]

  • 8. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, Lee YS, Lee EJ, Lee KY, Kim TJ.
    Lung Cancer; 2015 Mar 29; 87(3):311-7. PubMed ID: 25617986
    [Abstract] [Full Text] [Related]

  • 9. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H, Yamamoto H, Sakaguchi M, Shien K, Tomida S, Shien T, Ikeda H, Hatono M, Torigoe H, Namba K, Yoshioka T, Kurihara E, Ogoshi Y, Takahashi Y, Soh J, Toyooka S.
    Cancer Sci; 2018 Oct 29; 109(10):3183-3196. PubMed ID: 30098066
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K, Hou H, Liang Y, Zhang X.
    BMC Cancer; 2020 Apr 16; 20(1):328. PubMed ID: 32299384
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Research Progress of the Role of EMT in EGFR-TKIs Resistance 
of Non-small Cell Lung Cancer].
    Yu L, Huang S, Lv W, He Z, Hu J.
    Zhongguo Fei Ai Za Zhi; 2018 Dec 20; 21(12):907-911. PubMed ID: 30591098
    [Abstract] [Full Text] [Related]

  • 16. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.
    BMC Med; 2012 Mar 21; 10():28. PubMed ID: 22436374
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS, Cho BC, Soo RA.
    Lung Cancer; 2016 Mar 21; 93():59-68. PubMed ID: 26898616
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Epidermal Growth Factor Receptor targeting in non-small cell lung cancer: revisiting different strategies against the same target.
    Castañón E, Martín P, Rolfo C, Fusco JP, Ceniceros L, Legaspi J, Santisteban M, Gil-Bazo I.
    Curr Drug Targets; 2014 Mar 21; 15(14):1273-83. PubMed ID: 25511613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.